Abstract
Of all the molecular alterations that may have predictive value in non-small cell lung cancer (NSCLC), testing for EGFR mutations is usually the first step in determining course of adjuvant therapy. Activation of EGFR mutations, and perhaps amplification, predicts the response of NSCLC to tyrosine kinase inhibitors (TKIs). The presence of activating KRAS mutations predicts resistance to TKI therapy, but the value of this test is questionable in NSCLC given that the coexistence of both EGFR and KRAS mutations in the same patient is extremely rare and the presence of a KRAS mutation may not have much different significance than the absence of an EGFR mutation. In patients who are considered for gemcitabine therapy, measurement of ribonucleotide reductase subunit 1 (RRM1) expression levels may help predict which patients are less likely to respond, as higher levels of RRM1 have been shown to overcome the anti-metabolite of this drug. Similarly, in patients being considered for platinum-based therapy, determination of excision-repair cross complementing-1 protein (ERCC1) expression level may help predict which patients are less likely to respond, given that ERCC1 repairs platinum-induced DNA damage. The use of these predictive factors ideally will help target therapy to individual tumors to achieve the best chance for long-term survival and to avoid side effects from medications that are unlikely to have any effect. Further studies will continue to refine testing and treatment algorithms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ALK:
-
Anaplastic lymphoma kinase
- ARMS:
-
Amplification refractory mutation system analysis
- dNTP:
-
Deoxyribonucleoside triphosphate
- EGFR:
-
Epidermal growth factor receptor
- ELM4:
-
Echinoderm microtubule-associated protein-like 4
- ERCC1:
-
Excision-repair cross complementing-1 protein
- ERK:
-
Extracellular signal-regulated kinase
- FISH:
-
Fluorescence in-situ hybridization
- IHC:
-
Immunohistochemistry
- LOH 3p:
-
Loss of heterozygosity of 3p
- MASI:
-
Mutant allele-specific imbalance
- MEK:
-
MAPK/ERK kinase
- MRP:
-
Multidrug resistance protein
- NSCLC:
-
Non-small cell lung cancer
- PI3K:
-
Phosphoinositide 3-kinase
- PTEN:
-
Phosphatase and tensin homolog
- RRM1:
-
Ribonucleotide reductase subunit 1
- SNP:
-
Single-nucleotide polymorphisms
- TKI:
-
Tyrosine kinase inhibitors
References
Bepler G, Begum M, Simon GR (2008) Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 15(2):130–139
Ikeda N, Nagase S, Ohira T (2009) Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann Thorac Cardiovasc Surg 15(3):144–149
Kelly K et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19(13):3210–3218
Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98
Emery IF et al (2009) Response to gefitinib and erlotinib in non-small cell lung cancer: a retrospective study. BMC Cancer 9:333
Seike M et al (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 106(29):12085–12090
Mountzios G et al (2010) Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol 75(2):94–109
Helland A, Brustugun OT (2009) Lung cancer in smokers and never-smokers. Tidsskr Nor Laegeforen 129(18):1859–1862
Subramanian J, Govindan R (2008) Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 9(7):676–682
Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6(2):201–205
Rudin CM et al (2009) Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 15(18):5646–5661
Toh CK et al (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24(15):2245–2251
Holm B et al (2009) Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27(26):4254–4259
Sheth S (2010) Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am J Health Syst Pharm 67(1 Suppl 1):S9–S14
Hotta K et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2(7):632–637
Pignon JP et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559
Bepler G et al (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112–1118
Toloza EM, Roth JA, Swisher SG (2000) Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 18(2):91–99
Hommura F et al (1999) Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 81(4):696–701
Mohamed S et al (2007) Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer 109(12):2506–2514
Kim SJ et al (2010) Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 27(1):91–97
Hirsch FR et al (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4):752–760
Toffalorio F et al (2010) Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. Pharmacogenomics J 10(3):180–190
Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20(10):851–855
Shepherd FA et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132
Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animals. J Biol Chem 237:1555–1562
Cetin Z et al (2010) Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 27(3):853–860
Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301–308
Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817–1824
Lord RV et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8(7):2286–2291
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137
Sordella R et al (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687):1163–1167
Ji H et al (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9(6):485–495
Politi K et al (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20(11):1496–1510
Uramoto H, Mitsudomi T (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96(6):857–863
Gerber DE (2008) EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res 69(6):359–372
Hirsch FR et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24(31):5034–5042
Park IH et al (2009) Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 28(6):791–799
Parra HS et al (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br J Cancer 91(2):208–212
Fukuoka M et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12):2237–2246
Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500
Tsao MS et al (2005) Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144
Ichihara S et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120(6):1239–1247
Bonomi PD, Buckingham L, Coon J (2007) Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13(15 Pt 2):s4606–s4612
Pao W et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36):13306–13311
Lynch TJ et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
Kim SO et al (2008) Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14(10):3083–3088
Thatcher N et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–1537
Eberhard DA et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909
Zhu CQ et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(26):4268–4275
Kosaka T et al (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4(1):22–29
Mulloy R et al (2007) Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67(5):2325–2330
Chung BM et al (2009) The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 28(16):1821–1832
Greulich H et al (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2(11):e313
Kalikaki A et al (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69(1):110–115
Toyooka S et al (2007) The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 13(19):5763–5768
Shigematsu H et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–346
Bell DW et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081–8092
Matsuo K et al (2007) Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case–control study in Japanese. Cancer Sci 98(1):96–101
Leidner RS et al (2009) Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 27(33):5620–5626
Jang TW et al (2009) EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 24(1):48–54
Yatabe Y et al (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29(5):633–639
Capuzzo F et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655
Lee YJ et al (2010) Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 28(3):487–492
Adams VR, Harvey RD (2010) Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. Am J Health Syst Pharm 67(1 Suppl 1):S3–S9, quiz S15–S16
Han SW et al (2006) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12(8):2538–2544
Takano T et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(28):6829–6837
Miller VA et al (2008) Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26(9):1472–1478
Yoshioka H et al (2010) A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 5(1):99–104
Douillard JY et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28(5):744–752
Yoshida K et al (2010) Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol 136(4):527–535
Marks JL et al (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3(2):111–116
Casorzo L et al (2009) Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. Diagn Pathol 4:36
Varella-Garcia M et al (2009) EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 62(11):970–977
Sholl LM et al (2009) Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 69(21):8341–8348
Dziadziuszko R et al (2007) Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 18(3):447–452
Schneider CP et al (2008) Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 3(12):1446–1453
Crino L et al (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26(26):4253–4260
Mathieu A et al (2010) Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 69(1):46–50
Perez-Soler R et al (2004) Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 22(16):3238–3247
Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274(19):13176–13180
Etienne-Grimaldi MC et al (2005) Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 16(6):934–941
Liu W et al (2003) Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9(3):1009–1012
Schittenhelm MM et al (2009) Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 8(3):481–489
Ceppi P et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825
Alexandrescu DT, Kauffman CL, Dasanu CA (2009) Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 15(3):4
Peus D, Hamacher L, Pittelkow MR (1997) EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 109(6):751–756
Giovannini M et al (2009) Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol 2009:849051
Wacker B et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13(13):3913–3921
Regales L et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119(10):3000–3010
Inukai M et al (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66(16):7854–7858
Marchetti A et al (2009) Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11(10):1084–1092
Pao W et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73
Kobayashi S et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792
Kosaka T et al (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12(19):5764–5769
Pao W et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17
Vikis H et al (2007) EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 67(10):4665–4670
Balak MN et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12(21):6494–6501
Engelman JA et al (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116(10):2695–2706
Soh J et al (2009) Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4(10):e7464
Zhuang HQ et al (2009) The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J Exp Clin Cancer Res 28:123
Bianco R et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18):2812–2822
Rho JK et al (2009) The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 7(10):1736–1743
Bao R et al (2009) Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther 8(12):3296–3306
Faber AC et al (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106(46):19503–19508
Olaussen KA et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991
Zhou W et al (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10(15):4939–4943
Isla D et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15(8):1194–1203
West H et al (2009) Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 4(9 Suppl 2):S1029–S1039, quiz S1041–S1042
Azuma K et al (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3):326–333
Lee HW et al (2009) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65(3):377–382
Jeong SH et al (2010) Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 68(2):288–294
Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23
de Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13(7):768–785
Yin Z et al (2009) ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. J Exp Clin Cancer Res 28:153
Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291–1295
Yin Z et al (2009) Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 9:439
Cobo M et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19):2747–2754
Reynolds C et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27(34):5808–5815
Wang X et al (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 27(2):484–490
Ota S et al (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64(1):98–104
Shimizu J et al (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13(4):510–517
Wachters FM et al (2005) ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50(2):211–219
Simon GR et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978–983
Tibaldi C et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14(6):1797–1803
Li J et al (2009) Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 10(6):414–421
Rosell R et al (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2(11):e1129
Berg J (2002) Deoxyribonucleotides synthesized by the reduction of ribonucleotides through a radical mechanism. In: Biochemistry. W.H. Freeman, New York, pp 702–704
Xu X et al (2008) Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res 68(8):2652–2660
Nordlund P, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681–706
Tanaka H et al (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404(6773):42–49
Nakano K et al (2000) A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19(37):4283–4289
Chabes A et al (2003) Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase. Cell 112(3):391–401
Reichard P et al (2000) Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase. J Biol Chem 275(42):33021–33026
Caras IW, Martin DW Jr (1988) Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. Mol Cell Biol 8(7):2698–2704
Mathews CK (2006) DNA precursor metabolism and genomic stability. FASEB J 20(9):1300–1314
Gautam A, Li ZR, Bepler G (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22(14):2135–2142
Fan H et al (1997) The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 94(24):13181–13186
Zheng Z et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356(8):800–808
Gautam A, Bepler G (2006) Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66(13):6497–6502
Piao C et al (2009) Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene 28(21):2173–2184
Xue L et al (2006) Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res 66(4):1900–1905
Wang W et al (2009) Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 15(21):6630–6638
Souglakos J et al (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98(10):1710–1715
Rosell R et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325
Lee JJ et al (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70(2):205–210
Plunkett W et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11):3–10
Giovannetti E et al (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66(7):3928–3935
Davidson JD et al (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64(11):3761–3766
Bepler G et al (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24(29):4731–4737
Schettino C et al (2008) The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 9(4):252–262
Bepler G et al (2004) RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22(10):1878–1885
Bepler G et al (2002) Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20(5):1353–1360
Pitterle DM et al (1999) Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 10(9):916–922
Dong S et al (2010) RRM1 single nucleotide polymorphism −37CA correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 3:10
Bepler G, Sharma S, Gautam A, Smith P, Zheng Z, Hofmann J, Simonet G (2002) Tumor genotype, RRM1 expression and outcome of patients with lung cancer. Eur J Cancer 38:S82–S83
Feng JF et al (2009) Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 66(3):344–349
Bepler G et al (2005) Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47(2):183–192
Suda K, Tomizawa K, Mitsudomi T (2010) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29(1):49–60
Krontiris TG, Cooper GM (1981) Transforming activity of human tumor DNAs. Proc Natl Acad Sci U S A 78(2):1181–1184
Der CJ, Krontiris TG, Cooper GM (1982) Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A 79(11):3637–3640
Shimizu K et al (1983) Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A 80(8):2112–2116
Mao C et al (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69(3):272–278
Marchetti A et al (1996) Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 179(3):254–259
Forbes S et al (2006) COSMIC 2005. Br J Cancer 94(2):318–322
Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689
Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9(7):517–531
Sun P et al (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 128(2):295–308
Tuveson DA et al (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5(4):375–387
Weir BA et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898
Kendall J et al (2007) Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 104(42):16663–16668
Johnson L et al (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410(6832):1111–1116
Kobayashi T et al (1990) Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes. Cancer 66(2):289–294
Tsuchiya E et al (1995) High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. J Cancer Res Clin Oncol 121(9–10):577–581
Yatabe Y et al (2004) CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 203(2):645–652
Singh A et al (2009) A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489–500
Jackman DM et al (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15(16):5267–5273
Loriot Y et al (2009) Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6(9):528–534
Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4(12):1450–1454
Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566
Morris SW et al (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 267(5196):316–317
Shiota M et al (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9(6):1567–1574
Iwahara T et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4):439–449
Chiarle R et al (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8(1):11–23
Houtman SH et al (2007) Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules. Neuroscience 144(4):1373–1382
Pollmann M et al (2006) Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 312(17):3241–3251
Sasaki T et al(2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 46(10): 1773–1780
Takeuchi K et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15(9):3143–3149
Rikova K et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190–1203
Wong DW et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115(8):1723–1733
Shaw AT et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247–4253
Koivunen JP et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275–4283
Inamura K et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22(4):508–515
Soda M et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105(50):19893–19897
Rodig SJ et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15(16):5216–5223
Kwak E (2009) Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 27(suppl):152, abstr 3509
McDermott U et al (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68(9):3389–3395
Christensen JG et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12 Pt 1):3314–3322
Filipits M et al (2007) Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13(13):3892–3898
Reguart N et al (2008) BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 9(6):331–339
Taron M et al (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13(20):2443–2449
Potti A et al (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355(6):570–580
Chen HY et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356(1):11–20
Acknowledgements
We thank Dr. Jhanelle Gray, Assistant Member, Department of Thoracic Oncology and Experimental Therapeutics Program at Moffitt Cancer Center, for her help with the EGFR Summary.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Quigley, B., Ducker, S., Khalil, F. (2014). Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. In: Coppola, D. (eds) Molecular Pathology and Diagnostics of Cancer. Cancer Growth and Progression, vol 16. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7192-5_4
Download citation
DOI: https://doi.org/10.1007/978-94-007-7192-5_4
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7191-8
Online ISBN: 978-94-007-7192-5
eBook Packages: MedicineMedicine (R0)